Cargando…

PD-1(hi)TIM-3(+) T cells associate with and predict leukemia relapse in AML patients post allogeneic stem cell transplantation

Prognosis of leukemia relapse post allogeneic stem cell transplantation (alloSCT) is poor and effective new treatments are urgently needed. T cells are pivotal in eradicating leukemia through a graft versus leukemia (GVL) effect and leukemia relapse is considered a failure of GVL. T-cell exhaustion...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kong, Y, Zhang, J, Claxton, D F, Ehmann, W C, Rybka, W B, Zhu, L, Zeng, H, Schell, T D, Zheng, H
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2015
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4526784/ https://www.ncbi.nlm.nih.gov/pubmed/26230954 http://dx.doi.org/10.1038/bcj.2015.58

Ejemplares similares

Bone marrow CD8 T cells express high frequency of PD-1 and exhibit reduced anti-leukemia response in newly diagnosed AML patients
por: Jia, Bei, et al.
Publicado: (2018)

Blimp-1 impairs T cell function via upregulation of TIGIT and PD-1 in patients with acute myeloid leukemia
por: Zhu, Liuluan, et al.
Publicado: (2017)

The Elephant in The Room: AML Relapse Post Allogeneic Hematopoietic Cell Transplantation
por: Abou Dalle, Iman, et al.
Publicado: (2022)

Editorial: The Elephant in the Room: AML Relapse After Allogeneic Hematopoietic Cell Transplantation
por: Battipaglia, Giorgia, et al.
Publicado: (2022)

VISTA is highly expressed on MDSCs and mediates an inhibition of T cell response in patients with AML
por: Wang, Liru, et al.
Publicado: (2018)

Multi‐dimensional analysis identifies an immune signature predicting response to decitabine treatment in elderly patients with AML
por: Zhao, Chenchen, et al.
Publicado: (2019)

Comparison of the effect of DLI according to cell sources in relapsed AML after allogeneic stem cell transplantation
por: Park, Woochan, et al.
Publicado: (2023)

Salvage use of venetoclax-based therapy for relapsed AML post allogeneic hematopoietic cell transplantation
por: Joshi, Maansi, et al.
Publicado: (2021)

Feasibility and efficacy of salvage allogeneic stem cell transplantation in AML patients relapsing after autologous stem cell transplantation
por: Shumilov, Evgenii, et al.
Publicado: (2021)

P1379: OPTIMIZATION OF FLUDARABINE PHARMACOKINCETICS TO REDUCE THE RELAPSE INCIDENCE IN AML PATIENTS AFTER ALLOGENEIC STEM CELL TRANSPLANTATION
por: Thavayogarajah, T., et al.
Publicado: (2022)

Increased PD-1+Tim-3+ exhausted T cells in bone marrow may influence the clinical outcome of patients with AML
por: Tan, Jiaxiong, et al.
Publicado: (2020)

Peripheral Blood WT1 Expression Predicts Relapse in AML Patients Undergoing Allogeneic Stem Cell Transplantation
por: Malagola, Michele, et al.
Publicado: (2014)

P1426: WU-NK-101, AN ALLOGENEIC MEMORY NK CELL, FOR THE TREATMENT OF RELAPSE OR REFRACTORY (R/R) ACUTE MYELOID LEUKEMIA (AML)
por: Muth, J. J., et al.
Publicado: (2022)

Post-transplant cyclophosphamide alters immune signatures and leads to impaired T cell reconstitution in allogeneic hematopoietic stem cell transplant
por: Zhao, Chenchen, et al.
Publicado: (2022)

Phase 2 study of PD-1 blockade following autologous transplantation for patients with AML ineligible for allogeneic transplant
por: Solomon, Scott R., et al.
Publicado: (2023)

Successful Treatment of Early Relapsed High-Risk AML After Allogeneic Hematopoietic Stem Cell Transplantation With Biomodulatory Therapy
por: Kattner, Anna-Sophia, et al.
Publicado: (2020)

Relapse of NPM1-Mutated AML with Extramedullary Manifestation 17 Years after Allogeneic Hematopoietic Stem Cell Transplantation
por: Braune, Jan, et al.
Publicado: (2022)

Allogeneic hematopoietic cell transplantation for acute leukemia in first relapse or second remission
por: Lee, Je-Hwan, et al.
Publicado: (2010)

Donor selection for a second allogeneic stem cell transplantation in AML patients relapsing after a first transplant: a study of the Acute Leukemia Working Party of EBMT
por: Shimoni, Avichai, et al.
Publicado: (2019)

Leukemia relapse via genetic immune escape after allogeneic hematopoietic cell transplantation
por: Pagliuca, Simona, et al.
Publicado: (2023)

Leukemia relapse via genetic immune escape after allogeneic hematopoietic cell transplantation
por: Pagliuca, Simona, et al.
Publicado: (2023)

Pediatric donor cell leukemia after allogeneic hematopoietic stem cell transplantation in AML patient from related donor
por: Bobadilla-Morales, Lucina, et al.
Publicado: (2015)

A Case Report of the Second de Novo Acute Myeloid Leukemia (AML) Following Allogeneic Stem Cell Transplantation in a Patient with the First AML
por: Cho, Byung-Sik, et al.
Publicado: (2010)

Prognostic prediction of novel risk scores (AML-DRG and AML-HCT-CR) in acute myeloid leukemia patients with allogeneic hematopoietic stem cell transplantation
por: Cao, Weijie, et al.
Publicado: (2022)

Switch of the mutation type of the NPM1 gene in acute myeloid leukemia (AML): relapse or secondary AML?
por: Webersinke, G, et al.
Publicado: (2014)

P1390: THE EFFICACY AND SAFETY OF MODIFIED MELPHALAN AND BUSULFAN-BASED REGIMEN FOR ALLOGENEIC TRANSPLANTATION IN REFRACTORY/RELAPSED AML PATIENTS
por: Chen, S., et al.
Publicado: (2022)

Allogeneic Stem Cell Transplantation with Sequential Melphalan-Based Conditioning in AML: Residual Morphological Blast Count Determines the Risk of Relapse
por: Sockel, Katja, et al.
Publicado: (2022)

PB2413: SALVAGE THERAPY WITH VENETOCLAX AND A HYPOMETHYLATING AGENT FOR PATIENTS WITH AML RELAPSE AFTER ALLOGENEIC STEM CELL TRANSPLANTATION
por: Shaforostova, Inna, et al.
Publicado: (2023)

Cardiac Relapse of Acute Myeloid Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation
por: Facenda-Lorenzo, María, et al.
Publicado: (2016)

Chronic Myeloid Leukemia Relapsing 25 Years after Allogenic Stem Cell Transplantation
por: Reikvam, Håkon, et al.
Publicado: (2018)

The prevention of disease relapse after allogeneic hematopoietic cell transplantation in acute myeloid leukemia
por: Maffini, Enrico, et al.
Publicado: (2022)

Bone Marrow-Resident Vδ1 T Cells Co-express TIGIT With PD-1, TIM-3 or CD39 in AML and Myeloma
por: Brauneck, Franziska, et al.
Publicado: (2021)

Effects of T-Cell Depletion on Allogeneic Hematopoietic Stem Cell Transplantation Outcomes in AML Patients
por: Hobbs, Gabriela Soriano, et al.
Publicado: (2015)

Venetoclax in Combination with Decitabine for Relapsed T-Cell Acute Lymphoblastic Leukemia after Allogeneic Hematopoietic Cell Transplant
por: Rahmat, Leena T., et al.
Publicado: (2018)

Generalist in allogeneic hematopoietic stem cell transplantation for MDS or AML: Epigenetic therapy
por: Yang, Guancui, et al.
Publicado: (2022)

Bridging Strategies to Allogeneic Transplant for Older AML Patients
por: Hecker, Judith, et al.
Publicado: (2018)

Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial
por: Platzbecker, U, et al.
Publicado: (2012)

Prophylaxis and treatment of acute lymphoblastic leukemia relapse after allogeneic hematopoietic stem cell transplantation
por: Chen, Runzhe, et al.
Publicado: (2015)

Relapse of Acute Myeloid Leukemia after Allogeneic Stem Cell Transplantation: Prevention, Detection, and Treatment
por: Rautenberg, Christina, et al.
Publicado: (2019)

An isolated cardiac relapse after allogeneic hematopoietic stem cell transplantation for acute lymphoblastic leukemia
por: Chang, Kiju, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_q84n7m21910igfr4b10gocv673